| Literature DB >> 25760988 |
Stephane Fournier1, Patrick Taffé2, Dragana Radovanovic3, Erik Von Elm2, Beata Morawiec1, Jean-Christophe Stauffer4, Paul Erne3, Ahmed Beggah1, Pierre Monney1, Patrizio Pascale1, Juan-Fernando Iglesias1, Eric Eeckhout1, Olivier Muller1.
Abstract
BACKGROUND: Different studies have shown circadian variation of ischemic burden among patients with ST-Elevation Myocardial Infarction (STEMI), but with controversial results. The aim of this study was to analyze circadian variation of myocardial infarction size and in-hospital mortality in a large multicenter registry.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25760988 PMCID: PMC4356554 DOI: 10.1371/journal.pone.0119157
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics
| Population characteristics | Overall |
|---|---|
| Age in years (mean +/− SD) | 61.55 +/− 12.42 |
| Male gender (n;%) | 4,953 (79.59) |
| BMI (mean +/− SD) | 29.62 +/− 4.23 |
| Obesity (n;%) | 1067 (19.31) |
|
| |
| Killip I (n;%) | 5,321 (85.81) |
| Killip II (n;%) | 499 (8.05) |
| Killip III (n;%) | 96 (1.55) |
| Killip IV (n;%) | 285 (4.6) |
| Systolic blood pressure (in mmhg) (mean +/− SD) | 131.15 +/− 27.55 |
| Diastolic blood pressure (in mmhg) (mean +/− SD) | 78.71 +/− 18.53 |
| Heart rate (per minute) (mean +/− SD) | 75.93 +/− 18.25 |
|
| |
| aspirin (n;%) | 1,627 (27.08) |
| clopidogrel (n;%) | 330 (6.94) |
| prasugrel (n;%) | 10 (0.52) |
| oral anticoagulation (n;%) | 199 (3.34) |
| beta-blocker (n;%) | 1,313 (21.99) |
| ACE inhibitors (n;%) | 822 (13.84) |
| angiotensin II inhibitors (n;%) | 679 (11.95) |
| anti-calcium (n;%) | 549 (9.24) |
| amiodaron (n;%) | 3 (0.35) |
| nitrates (n;%) | 204 (3.43) |
| digoxin (n;%) | 35 (0.59) |
| diuretics (n;%) | 612 (12.26) |
| statins (n;%) | 1,354 (22.57) |
|
| |
| Past MI (n;%) | 739 (12.55) |
| Diabetes (n;%) | 631 (10.71) |
| Family history (n;%) | 1,470 (33.82) |
| Hypertension (n;%) | 2,966 (49.97) |
| Dyslipidemia (n;%) | 3,044 (53.76) |
| Smoking (n;%) | 2,740 (47.66) |
| Ischemic Heart Disease (n;%) | 820 (24.03) |
| Previous stable angina (n;%) | 743 (14.91) |
| Heart Failure with NYHA >2 (n;%) | 136 (2.31) |
| Chronic Lung Disease (n;%) | 195 (3.31) |
| Moderate to severe renal disease (n;%) | 179 (3.04) |
| Peripheral vascular disease (stade >2) (n;%) | 136 (2.31) |
|
| |
| posterior (n;%) | 688 (14.17) |
| lateral (n;%) | 243 (11.34) |
| inferior (n;%) | 2,430 (49.72) |
| anterior (n;%) | 2,781 (44.09) |
| undertermined (n;%) | 103 (2.13) |
|
| |
| GP IIb/IIIa antagonists (n;%) | 2,993 (48.56) |
| Creatinin on admission (μmol/l) (mean +/− SD) | 86.57 +/− 30.55 |
|
| |
| At the start: 0 (n;%) | 983 (70.06) |
| At the start: I (n;%) | 156 (11.12) |
| At the start: II (n;%) | 124 (8.84) |
| At the start: III (n;%) | 140 (9.98) |
| At the end: 0 (n;%) | 60 (1.52) |
| At the end: I (n;%) | 32 (0.81) |
| At the end: II (n;%) | 213 (5.39) |
| At the end: III (n;%) | 3,649 (92.29) |
|
| |
| Peak Ck in U/L (mean +/− SD) | 2,129.48 +/− 1889.75 |
| Alive at the end of hospitalization (n,%) | 6,000 (96.42) |